Dazomet

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dazomet

Property Description
Active ingredient Metronidazole
Primary Form Tablets, Capsules, IV Solution
Pharmacological class Antibiotic, Antiprotozoal Agent
Common use Addressing infections caused by specific susceptible microbes
Origin Synthetic Nitroimidazole Compound

What is Dazomet and its Active Ingredient, Metronidazole?

Dazomet is a pharmaceutical product containing the active ingredient Metronidazole, a synthetic substance classified as a nitroimidazole antimicrobial agent. This medication is a single-ingredient product used exclusively to address infections caused by specific organisms. Metronidazole functions as a prodrug, meaning it is administered in an inactive form, requiring chemical activation by the target pathogens (anaerobic bacteria and certain protozoa) to become effective. Metronidazole is clinically recognized for the treatment of serious infections caused by susceptible bacteria and parasites, reflecting its established utility in infectious disease management.

Dazomet's Classification: An Antibiotic and Antiprotozoal Agent

The medication is officially classified as both a synthetic antibacterial and an antiprotozoal agent. This dual classification reflects its unique capacity to eliminate two distinct classes of pathogens. Its highly selective toxicity is focused specifically on anaerobic bacteria—those capable of thriving without oxygen—and certain protozoa. Metronidazole is recognized on the Model List of Essential Medicines, confirming its established global importance as a core antimicrobial agent. Dazomet is supplied in multiple dosage forms, including film-coated tablets and a sterile solution for intravenous infusion, a variation that allows for use in hospital settings when oral administration is not feasible.

What is the General Purpose of Dazomet's Targeted Action?

The general purpose of Dazomet is to definitively clear the body of susceptible pathogenic anaerobic bacteria and protozoa through a direct and targeted killing action. The drug achieves this by interfering with the synthesis of essential nucleic acids inside the target organism, which is critical for its survival and reproduction. This mechanism results in a pronounced bactericidal effect, meaning it actively kills the susceptible pathogens, rather than just slowing their growth. The overall benefit is the effective elimination of infections caused by these particular microbial groups.

What side effects are possible with Dazomet?

Possible Side Effects and Safety Information

Official regulatory documents classify the potential side effects of Dazomet (metronidazole) across several physiological systems. The most commonly documented adverse reactions are generally related to the Gastrointestinal System and Nervous System.

Common and Less Common Systemic Effects

Adverse reactions classified as common include gastrointestinal symptoms such as nausea, vomiting, diarrhea, abdominal cramping, and headache. Patients may also experience dizziness or an unpleasant metallic taste.

Reactions categorized by System-Organ Class (SOC) include:

  • Nervous System Disorders: Headache, dizziness, and peripheral neuropathy.
  • Gastrointestinal Disorders: Nausea, vomiting, diarrhea, and metallic taste.
  • Skin Disorders: Rash and itching.

Documented Serious Adverse Reactions

Official labeling highlights several serious adverse reactions, primarily concerning the Central Nervous System and the Skin. These include convulsive seizures, encephalopathy, and peripheral neuropathy. Cases of Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also documented.

Safety Considerations and Restrictions

Regulatory sources provide explicit constraints for certain populations. The use of metronidazole is contraindicated in patients with Cockayne Syndrome due to the risk of severe, sometimes fatal, hepatotoxicity, which may have a very rapid onset. Patients with severe hepatic impairment require monitoring for adverse events due to drug accumulation. The label also notes that peripheral neuropathy is a potential effect associated with prolonged or high-dose therapy. The official labeling carries a carcinogenicity warning based on animal studies.

Overdose and Emergency Response

Dazomet is a pesticide and soil fumigant; therefore, an overdose or accidental exposure requires immediate medical attention. Intentional or unintentional exposure to Dazomet can be harmful due to its toxicity and its breakdown product, methyl isothiocyanate (MITC), which is corrosive and highly irritating.

Signs and Symptoms of Overexposure

Exposure can occur through skin contact, inhalation, or ingestion, leading to varying degrees of injury. Key signs of overexposure may include:

  • Respiratory: Irritation of the nose and throat, coughing, wheezing, shortness of breath, or breathing difficulties.
  • Skin/Eyes: Severe irritation, redness, pain, and potentially chemical burns or irreversible damage to the eyes.
  • Gastrointestinal: Abdominal pain, nausea, and vomiting, especially following ingestion.
  • Neurological: Headache, dizziness, and confusion.

When to Seek Immediate Help

Any known or suspected exposure to Dazomet should be treated as a medical emergency. Do not wait for severe symptoms to appear.

Exposure Route Immediate Action
Inhalation Move to fresh air immediately. If not breathing, perform artificial respiration.
Skin/Clothing Contact Remove contaminated clothing and rinse skin thoroughly with plenty of water.
Eye Contact Rinse eyes gently with water for at least 15 minutes. Remove contact lenses if applicable.
Ingestion Do not induce vomiting unless directed by a poison control center or doctor. Have the person sip water if conscious.

In the event of exposure, call your local emergency services or a poison control center immediately for instructions. Have the product container or label available when seeking help.

Therapeutic Uses of Dazomet

Dazomet is used to address infections caused by both susceptible bacteria and protozoa, focusing on specific therapeutic areas related to antimicrobial and antiparasitic management.

What Dazomet Treats: Main Uses and Benefits

Dazomet is applied across domains where additional symptomatic support is needed to manage infections caused by certain anaerobic bacteria and parasites. It is commonly used for conditions presenting with systemic or localized discomfort, such as those involving internal sites, and for parasitic conditions like amebiasis, giardiasis, and trichomoniasis. The medication is also relevant in managing symptoms related to inflammatory or irritative states of the urogenital tract, such as bacterial vaginosis. Furthermore, it is relevant for easing symptoms associated with localized discomfort, including dental concerns and the inflammatory symptoms of rosacea.

Dazomet is commonly used to help with symptoms that interfere with daily comfort. It is applied in scenarios where additional management of discomfort is required, such as during acute episodes of severe symptoms related to physical discomfort.

“Dazomet supports the patient during difficult episodes by easing distress and contributing to easing the overall symptom load.”

This assistance contributes to improved day-to-day comfort and supports the patient in maintaining functional stability during symptomatic phases.

Quick Fact: Relief for Symptom Clusters
Dazomet is relevant for easing groups of symptoms related to gastrointestinal distress, urogenital irritation, and systemic fever that may become disruptive during flare-ups.

Regulatory References

  1. NIH MedlinePlus overview of Metronidazole

Eligibility and Restrictions for Use

Who can and cannot use Dazomet? (Metronidazole)

Official regulatory documentation defines eligibility for Dazomet based on absolute contraindications and mandatory restrictions related to health status and age.

Absolute Contraindications (Must Not Use) Conditional Restrictions (Use with Caution)
Prior hypersensitivity to metronidazole or other nitroimidazole derivatives. Severe Hepatic Impairment (Child-Pugh C), where a 50% dosage reduction is recommended.
Use of Disulfiram within the last two weeks. End-Stage Renal Disease (ESRD), due to metabolite accumulation risk.
Concurrent consumption of alcohol or products containing propylene glycol. Central Nervous System (CNS) diseases, due to potential neurological effects.
Patients with Cockayne syndrome, due to the risk of fatal acute liver failure. History of Blood Dyscrasias or Leukopenia.

Age-Related Eligibility: Safety and effectiveness for many approved adult uses are not established in the general pediatric population. For the elderly, caution is advised due to potential age-related organ dysfunction, which may require monitoring or dose adjustment. Extended-release forms are not recommended for females before the start of menstruation.

Pregnancy and Lactation: Use is contraindicated during the first trimester of pregnancy for some indications. Metronidazole is secreted into breast milk; while use is possible, temporary discontinuation of breastfeeding may be advised following certain high-dose regimens.

What should I know about interactions with other medicines?

Dazomet (Metronidazole) exhibits officially documented interaction patterns with various medicinal products and substances, categorized by pharmacodynamic and pharmacokinetic effects as described in regulatory documents. A central focus is on prohibited combinations: co-administration with Disulfiram is strictly contraindicated, and regulatory mandates require separation by a minimum of 14 days due to the risk of psychotic reactions. Similarly, the use of Alcohol/Ethanol or products containing Propylene Glycol is officially prohibited during therapy and for at least 72 hours following the final dose, based on the risk of a severe disulfiram-like reaction.

The official profile details interactions that alter the plasma concentration of co-administered medicines, such as the potentiation of Oral Anticoagulants (Warfarin) by reducing their clearance, which necessitates monitoring of prothrombin time. Dazomet also reduces the clearance of the cytotoxic agent 5-Fluorouracil (5-FU), increasing the risk of 5-FU toxicity. Conversely, agents like Phenytoin and Phenobarbital are documented to increase Metronidazole metabolism, which reduces Metronidazole's exposure.

Population-specific constraints are also documented. Patients with severe hepatic impairment may experience significant Metronidazole accumulation due to reduced clearance. Furthermore, Dazomet is officially contraindicated for individuals with Cockayne Syndrome due to the documented risk of severe hepatotoxicity.

Mechanism of Action

How Dazomet Works: Mechanism of Action

Dazomet functions as an inert pro-drug that is activated by hydrolysis in the presence of moisture, rapidly releasing the volatile gas Methyl Isothiocyanate (MITC). This mechanism is important because the vapor-phase diffusion of MITC provides broad and uniform exposure to target biological agents throughout the medium in which activation occurs.

The active metabolite, MITC, is a highly reactive electrophile that acts by performing irreversible covalent modification of nucleophilic functional groups found on biological targets, including enzymes and nucleic acids (DNA/RNA). This chemical alteration leads to the non-specific deactivation of essential proteins and the structural damage of genetic material.

The molecular damage initiates a cascade that halts fundamental life processes, such as cellular respiration and genetic replication, leading to cytotoxicity and cell death. This systemic biocidal effect results in the elimination of a wide range of biological agents across the affected medium.

Dosage and Administration Information

How to Use Dazomet: General Administration Guidelines

This section outlines the methods and high-level dosing rules for Dazomet (Metronidazole), focusing strictly on administration protocols.


Approved Routes and Schedules

Administration is utilized via multiple routes to address different clinical needs. The methods include oral (tablets, capsules, suspension) and intravenous (IV) infusion for systemic delivery, and topical/intravaginal forms for localized use. The dosing schedule is defined for short, time-limited courses, with standard maintenance regimens frequently requiring administration two or three times a day (BID or TID).


Standard Dosing and Procedural Requirements

Specific dose ranges and administration steps are defined for clinical use. For serious infections, intravenous therapy often starts with an initial loading dose followed by scheduled maintenance doses (e.g., 7.5 mg/kg every 6 hours). Treatment courses are generally short, typically ranging from 5 to 10 days depending on the infection being addressed.

Administration Requirement General Instruction Rationale
Oral Intake Condition Immediate-release forms can be taken with or without food; extended-release tablets must be taken on an empty stomach and swallowed whole. Prevents formulation damage and ensures proper absorption.
IV Infusion Solution must be administered via slow infusion over 30 to 60 minutes. Ensures appropriate drug concentration and reduces procedural risk.

Population-Specific Use

Specific dosage adjustments are established for certain patient groups. A 50% reduction in the metronidazole dosage is recommended for patients diagnosed with severe hepatic impairment due to changes in drug clearance. Dosing adjustments are generally not needed for patients with renal impairment, but may be considered for patients on hemodialysis.

Recent Clinical Evidence

Dazomet is primarily known as a soil fumigant pesticide used in agriculture to manage fungi, nematodes, and certain weeds in crops like strawberries, tomatoes, and ornamental plants. Its main use is as a pre-plant treatment for soil. When applied, it breaks down to release a compound called methyl isothiocyanate (MITC), which is the principal agent responsible for its activity in the soil.

While dazomet is widely used in agricultural contexts, clinical evidence regarding its therapeutic use as a human drug is generally not recognized in major regulatory frameworks. Medical references indicate that a different, unrelated compound, the antibiotic Metronidazole, has been sold under the brand name 'Dazomet' in some regions, which may lead to confusion.

Non-Human Clinical Context

Recent scientific studies focus on its efficacy and environmental profile as a soil treatment. Research in controlled environments has shown that dazomet application is associated with alterations in soil microbial communities, particularly a reduction in the relative abundance of certain soil-borne fungal pathogens. For example, studies on continuous cropping systems for organisms such as morel mushrooms reported that dazomet treatment was associated with a significant increase in yield, which was attributed to the observed changes in the soil's microbial balance.

Safety and Regulatory Status

In the United States, the Environmental Protection Agency (EPA) has classified dazomet as a restricted-use pesticide for its soil fumigant applications. The agency's assessments have identified potential human health risks, primarily from acute inhalation exposure for handlers and bystanders, leading to requirements for risk mitigation measures such as buffer zones and handler protection. Toxicological studies indicate potential for irritation to the eyes and skin, and its decomposition product, MITC, is also an irritant. Due to its chemical profile and primary use, dazomet is not a subject of human clinical trials for medical treatment.

Frequently Asked Questions (FAQ)

Common questions about Dazomet (FAQ)


Q: What are the official safety classifications for Dazomet and its breakdown products?

Official regulatory agencies classify Dazomet as a Restricted Use Pesticide (RUP) due to its toxicity, particularly the risks associated with acute inhalation exposure. This classification indicates its use is highly regulated and generally restricted to certified professionals. In certain jurisdictions, the chemical may also be designated as a Toxic Air Contaminant (TAC).


Q: What types of personal protective equipment (PPE) are described as necessary for handling Dazomet?

Regulatory documents detail the personal protective equipment (PPE) that handlers are specified to use to minimize exposure. This typically includes chemical-resistant coveralls, long pants, chemical-resistant gloves (such as Nitrile or Butyl), footwear, eye protection, and a NIOSH-approved respirator. These specific requirements are defined on the official product label.


Q: What are the official guidelines regarding the safe storage of Dazomet products?

Official guidelines recommend storing the product in a dry place under ambient temperatures, often below 35 C. It is important to protect the chemical from moisture to prevent premature activation. Storage must be conducted according to the guidelines provided in the official product documents.


Q: What is the recommended procedure if Dazomet granules are accidentally spilled or released?

Official guidance for spills details procedures that typically involve isolating the area and removing all ignition sources. For small spills, this often includes dampening the spilled material and then transferring it to a sealed container for subsequent disposal. Disposal of all spilled material must strictly follow local, state, and national regulatory requirements.


Q: Why is Dazomet often mentioned as an alternative to methyl bromide?

Dazomet is listed by regulatory and research bodies as an alternative to methyl bromide, a fumigant that was phased out due to its ozone-depleting properties. Dazomet serves a similar purpose as a non-selective soil fumigant in agricultural pest management. Its use reflects an official shift toward different regulatory-approved chemical controls.


Q: Is Dazomet generally available to the public, or is it a restricted-use chemical?

Dazomet is officially classified as a Restricted Use Pesticide (RUP). This classification is due to its acute inhalation toxicity risks. Consequently, its sale and use are officially limited only to certified applicators or those under their direct supervision.


Q: What specific soil conditions, such as temperature and moisture, are required for Dazomet to be effective?

Official guidance specifies that for the product to be effective, soil temperatures should be within the range of 10 C to 25 C. Adequate soil moisture, typically 60% to 70% of the water-holding capacity, must be maintained for several days both before and after application to ensure proper chemical activation.


Q: What is the recommended waiting period between Dazomet application and planting a new crop?

The recommended waiting period before planting a new crop is generally 2 to 4 weeks under optimal conditions. This duration is mandatory and ensures that all gaseous residues have dissipated. The final waiting time is subject to extension based on factors like soil type and composition.


Q: Is it possible for Dazomet to cause phytotoxicity or damage to crops if used improperly?

Regulatory guidance implicitly suggests a risk of phytotoxicity (plant damage) if the product is not used according to specifications. Official documentation mandates that all gaseous residues must be completely removed from the soil before seeding or planting. Not adhering to the mandatory waiting period may result in phytotoxicity or damage to the new crop.


Q: Are there any reported health risks from accidental exposure to Dazomet granules?

Official safety data sheets describe Dazomet granules as toxic by ingestion and inhalation. The compound is also noted as a severe irritant to the eyes and a mild primary skin irritant. Regulatory documents detail strict handling protocols designed to address these reported health risks.


Q: What are the typical symptoms of exposure to the gaseous breakdown product, MITC?

The vapors of the breakdown product, MITC, are described as highly irritating to the eyes, skin, and mucous membranes. Experiencing symptoms such as burning of the eyes and nose, or tearing, is considered an early sign of exposure to the vapors. Official safety information notes that if these signs occur, regulatory protocols detail that handlers must immediately leave the exposure area.


Q: Does Dazomet pose a risk to non-target organisms, such as beneficial soil microbes or pollinators?

Regulatory agencies specify that Dazomet is very toxic to aquatic organisms, indicating a potential risk to water life if precautions are not followed. Furthermore, official hazard ratings note potential acute risks of concern for certain birds and mammals if exposed to unincorporated granules. Buffer zones are required to protect surrounding environmental areas.


Q: How is Dazomet categorized regarding its potential for groundwater contamination?

In certain jurisdictions, Dazomet is officially designated by regulatory agencies as a Potential Groundwater Contaminant. This designation is based on the chemical's profile and necessitates specific use limitations and monitoring requirements to protect water resources.


Q: Are there any environmental restrictions on using Dazomet near bodies of water or aquatic life?

Yes, official restrictions are mandated due to the chemical's high toxicity to aquatic organisms. Regulatory guidelines require the establishment of mandatory buffer zones of specified distances. These zones are specified as a mitigation measure intended to reduce potential risk to nearby aquatic and environmental areas.


Q: What are the mandatory application procedures described to prevent gas loss after soil treatment?

Regulatory guidance describes mandatory procedures that include immediate soil sealing after application. This is achieved by techniques such as compressing the soil with a roller, immediate irrigation (water seal), and/or covering the soil with a polyethylene tarp to reduce gas escape and maintain moisture.


Q: What does the term 'soil sterilant' mean in the context of Dazomet's use?

The official documentation describes the product as possessing soil-sterilizing properties. This term means that the chemical breaks down to a gas (MITC) that causes non-selective deactivation and elimination of a broad spectrum of living organisms, including unwanted fungi, weeds, and nematodes, within the treated soil medium.


Q: Is Dazomet the same chemical compound as Metam Sodium?

Official regulatory documents consistently list Dazomet alongside Metam Sodium/Potassium as separate but related soil fumigants. While they are different chemical compounds, both are designed to break down into the same active fumigating agent, Methyl Isothiocyanate (MITC).


Q: Why does Dazomet have different trade names, such as Basamid?

Dazomet is the officially registered active ingredient contained within products that are marketed under various brand names. Official regulatory documents, such as handler safety guides, confirm that Dazomet is referenced by specific trade names like Basamid G.


Q: How does high organic matter content in the soil affect Dazomet’s performance?

Regulatory guidance notes that high organic content in the soil can result in the adsorption of the active material by the organic matter. This potential for adsorption may require the user to adjust the application rate or extend the mandatory waiting period before planting, as specified by the product label.


Q: Are there specific regulations for the use of Dazomet in residential or close-proximity areas?

Yes, regulatory bodies mandate specific safety requirements to protect bystanders near fumigated fields. These measures include the required use of buffer zones of specified distances and other safety protocols intended to protect individuals who reside, work, or spend time near application sites.


Q: What are the acute exposure guideline levels (AEGLs) for MITC gas?

The EPA Fumigant Management Plan establishes an action level where handlers must stop work if air concentrations of the gas are greater than or equal to 600 ppb (0.6 ppm) in the work area. This regulatory threshold is used to ensure safety during handling.


Q: Is the pungent odor associated with Dazomet a reliable indicator of dangerous exposure levels?

Official handler safety information indicates that the irritation, such as tearing or burning of the eyes and nose, serves as a sensory warning of exposure to the vapors. Handlers are directed to treat this sensory warning as an immediate prompt to leave the area, according to regulatory protocols.


Q: Have regulatory bodies conducted re-evaluations of Dazomet's safety profile in recent years?

Yes, regulatory bodies across multiple jurisdictions have conducted recent re-evaluations of Dazomet's safety profile. These official reviews, such as those from Health Canada and the US EPA, have led to updated required mitigation measures and amended conditions of registration.


Q: What type of research has been conducted on the potential long-term health effects of repeated exposure to Dazomet/MITC?

Safety reviews indicate that limited evidence exists suggesting that repeated or long-term occupational exposure may potentially produce cumulative health effects. These effects are described as involving organs or biochemical systems, highlighting the need for strict adherence to handling protocols.


Q: Is there a required period of time before workers or residents can re-enter a Dazomet-treated area?

Yes, official product labels establish a mandatory Entry Restricted Period for the treated area. This period begins at the start of application and expires only after a specified time has passed and any required actions, such as removing tarps, have been completed.


Q: What is the difference in toxicity between the Dazomet parent compound and the MITC breakdown product?

Dazomet, the solid granule compound, is documented as toxic by ingestion and is a dermal irritant. The Methyl Isothiocyanate (MITC) breakdown product, however, is a highly volatile gas primarily associated with acute inhalation exposure and severe irritation to the eyes and mucous membranes.


Q: Are there different application methods described for Dazomet (e.g., mechanical incorporation vs. water incorporation)?

Official guidance details various application methods, including the mechanical incorporation of the granules into the soil. This is followed by sealing methods that use either plastic tarps or irrigation (water incorporation) to activate the chemical and prevent the gas from escaping.


Q: What is the chemical family or class that Dazomet belongs to?

Regulatory documents classify the active ingredient, Dazomet, as belonging to the Organosulfur chemical class. This classification is used by agencies for regulatory purposes, including tracking and toxicity assessment.


Q: Are there specific crop uses for Dazomet that are currently being researched or reviewed?

Regulatory documents indicate that specific uses are subject to ongoing review and registration amendments. For example, some non-fumigant uses (like as a preservative in paper and coatings) have been officially cancelled following re-evaluation, focusing its registration on specific crop uses.


Q: What is the regulatory status of Dazomet in key international jurisdictions (e.g., EU, Japan)?

Regulatory bodies outside the US, such as Health Canada's Pest Management Regulatory Agency (PMRA), have recently issued re-evaluation decisions concerning its use. These official documents outline required mitigation measures and amended conditions of registration in their respective jurisdictions.


Q: Does Dazomet primarily act as a nematicide, fungicide, or herbicide?

Dazomet is officially classified as a non-selective fumigant that exhibits multiple actions. Regulatory documents list its functions as a Nematicide (kills nematodes), Fungicide (kills fungi), and Herbicide (kills weeds), among other classifications.


Q: Can Dazomet be used in covered areas like greenhouses or hoop houses?

Yes, official labels and use-site limitations confirm Dazomet is registered for the pre-planting control of listed pests in specific covered structures. These approved application sites include greenhouses and hoop houses, provided all safety and use protocols are followed.


Q: What is the role of soil sealing (e.g., with tarps or water) in the effectiveness of Dazomet?

Soil sealing is a mandatory application procedure described in official guidance. Its role is twofold: to prevent the escape of the active gas (MITC) from the soil and to maintain the required soil moisture level for the chemical's proper activation.


Q: Why does Dazomet require adequate soil moisture to be activated?

Dazomet is classified as a pro-drug that requires moisture to function effectively. The active gas, Methyl Isothiocyanate (MITC), is generated only through a chemical breakdown reaction (hydrolysis) that is dependent on the presence of appropriate soil moisture content.


Q: Is the primary mode of action on pests well-understood and documented?

Yes, the primary mode of action is documented by regulatory bodies. Dazomet rapidly decomposes into the active gas, MITC, which performs irreversible chemical modification of essential biological components, such as enzymes and nucleic acids, leading to the death of the target organisms.


Q: Are there official recommendations for disposal of Dazomet residues or containers?

Official guidance instructs users to treat or dispose of all unused product and waste materials in accordance with all local, state/provincial, and national requirements. It is officially recommended to avoid disposal into waste treatment facilities.


Q: Does the application rate of Dazomet vary significantly based on the type of pest being targeted?

Yes, regulatory documents indicate that application rates are specifically defined on the product label and vary based on the intended use and the pest being targeted. Maximum label rates may also be subject to change following government re-evaluation decisions.

How should Dazomet be stored and disposed of?

The official storage and disposal requirements for Dazomet (Metronidazole) are defined by government regulatory agencies to ensure product quality and safe handling.

Official Storage Constraints

Requirement Rule Constraint Type
Temperature Store most forms at or below 25 C (77 F). Mandatory
IV Solution Must not be refrigerated or frozen. Prohibited
Protection Must be protected from light. Mandatory
Packaging Keep in the original container and keep tightly closed. Packaging

Handling and Disposal

The intravenous solution is for single use only, and any unused portion must be discarded immediately after use. Disposal of all unused or expired medicinal product and waste material must be conducted in accordance with local regulatory requirements. This ensures responsible end-of-life management and prevents environmental contamination, which is a key regulatory concern.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dazomet found in:

A-Z Index: